Build

ASCO 2026: GLP-1s may reduce metastatic progression of some obesity-related cancers

2 min read

ASCO 2026: GLP-1s may reduce metastatic progression of some obesity-related cancers

Provenance: conference research via a reputable oncology network

Real-world retrospective data presented at the 2026 ASCO Annual Meeting (May 29–Jun 2, Chicago), reported by Oncology Central and corroborated by ASCO and The ASCO Post. Higher-tier than the YouTube/anecdote sources — but still observational (association, not causation).

Key findings

  • Using the TriNetX Global Health Research Network, investigators propensity-matched 12,112 patients with stage I–III cancer, comparing GLP-1 receptor agonists vs DPP-4 inhibitors started after diagnosis.
  • Seven obesity-related cancers were examined (breast, prostate, NSCLC, colorectal, hepatocellular, renal, pancreatic). GLP-1 RAs were associated with reduced metastatic progression in four: lung, breast, colorectal, and liver.
  • Largest signal in breast cancer — risk of death down ~45%.
  • GLP-1 receptor expression was associated with overall survival, suggesting GLP-1 signaling may be involved in progression of these cancers.

Why it matters for this base

  • A notable counterpoint to the cancer-caution framing on angiogenic peptides (BPC-157, TB-500, GHK-Cu): unlike those, GLP-1 receptor agonists show a cancer-protective signal in obesity-related cancers — supporting their #1 longevity ranking.

Caveats

  • Observational/real-world; needs randomized confirmation. A separate ASCO release also noted GLP-1 RAs modestly reduce incidence of 14 obesity-related cancers in people with diabetes.

Corroborating sources

  • ASCO press release & The ASCO Post (May 2026); Oncology Nursing News; US News Health.
  • Primary abstract: J Clin Oncol 2026;44(16_suppl):3143 (propensity-matched analysis across seven solid tumors), ascopubs.org.
  • Further 2026 corroboration: ASCO 2026 update — ~34% mortality reduction across six cancer types (Pharmacy Times); a separate colon-cancer + obesity cohort (The ASCO Post, Jan 25 2026) — lower mortality, MI, sepsis, and ventilation need; preclinical lung-cancer tumor-control paper (PMC12513478). Direction consistent; all observational/preclinical.

Graph View

Backlinks